Merrill Brink News Reviews and Opinion: New Market Opportunities in Emerging Countries Cause Life Science Companies to Re-Evaluate Translation & Localization Strategies

http://www.merrillbrink.com --Language translation services are becoming an even higher priority for life sciences companies targeting emerging markets for business growth.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Merrill Brink

Merrill Brink

New Market Opportunities in Emerging Countries Cause Life Science Companies to Re-Evaluate Translation & Localization Strategies

New York, US (PRWEB) February 21, 2013

Language translation services are becoming an even higher priority for life sciences companies targeting emerging markets for business growth. For many of these firms, according to a 2011 Jones Lang LaSalle report, “Asia is clearly an area of focus, particularly India and China. The scale and breadth of investment over the last decade in India and China suggests companies are looking to these countries as both revenue and margin opportunities, and as a destination for both manufacturing and R&D opportunities.”1

However, competition is tough in these markets and companies face escalating pressure to bring products to market without delay. In the race to win market share, companies have identified language translation and localization services as critical to their success. “Life sciences firms producing medical devices or pharmaceuticals are anticipating fast growing demand for translation, localization and cultural customization in Asian languages, especially those languages spoken by large populations of potential users and clinical trial participants in China and India,” noted Nataly Kelly, Chief Research Officer for the Common Sense Advisory.2

An additional trend, medical tourism, defined as patient movement from highly developed nations to less developed areas of the world for medical care3, is also fueling a growing demand for language translations in the medical field. As a recent Deloitte report noted, “Medical care in countries such as India, Thailand and Singapore can cost as little as 10 percent of the cost of comparable care in the United States. The price is remarkably lower for a variety of services and often includes airfare and a stay in a resort hotel. Thanks in part to these low-cost care alternatives, which almost resemble a mini-vacation, interest in medical tourism is strong and positive.”4

To position themselves for growth, many companies are re-evaluating their document translation practices to expedite and improve translation procedures for product, regulatory and marketing documentation without sacrificing quality or dramatically increasing costs. One area of opportunity may be found through the reduction of the number of language providers being used. According to the Common Sense Advisory, reliance on multiple translation and localization vendors is typical in life sciences, but centralized purchasing processes are not. Many large firms often have no idea how many suppliers they have across the organization.5 Firms may derive considerable quality and cost benefits by centralizing all translation and localization projects through a single vendor.

To accomplish this, companies will need a qualified language services provider (LSP) who offers the right combination of expertise, infrastructure and resources to fully support the needs of a life science company. The provider should have the following credentials:

  •     Documented, internationally recognized quality and risk management standards
  •     Content management system (CMS) support to streamline process development
  •     High-quality, documented method for qualifying and managing vendors and resources
  •     Web-based technology tools to foster efficiency
  •     Multilingual rebranding expertise

Life science businesses should ensure their LSP offers expert life science translators and linguists with specific subject matter expertise and experience in pharmaceutical, medical device and diagnostic, and/or biotechnology translation. Buyers should evaluate every potential partner according to standardized criteria to ensure no critical aspect is overlooked. Equally important, a well-qualified LSP should be able to provide client references of life science firms that are similar to the buyer’s profile.

References:
1 “Life Sciences Cluster Report: Global.2011,” Jones Lange LaSalle IP, Inc., 2011.
2 Inna Geller and Nataly Kelly, “How Life Sciences Companies Buy Translation,” Common Sense Advisory, October 15, 2010.
3 http://en.wikipedia.org/wiki/Medical_tourism.
4 “Medical Tourism, Consumers in Search of Value,” Deloitte Center for Health Solutions, 2008.
5 Inna Geller and Nataly Kelly.

Read the full article here: http://www.merrillbrink.com/emerging-countries-cause-life-science-companies-to-re-evaluate-translation-strategies-02182013.htm

About Merrill Brink International
Merrill Brink International (http://www.merrillbrink.com) is a leading provider of complete translation and language solutions for global companies and law firms, with special expertise in serving the legal, financial, life sciences, software, heavy machinery and corporate markets. A proven leader with more than 30 years of experience, Merrill Brink offers a wide range of language solutions including translation, localization, desktop publishing and globalization services.

Merrill Brink is recognized in the industry for its commitment to quality and its pioneering approach of leveraging technology to reduce costs, eliminate redundant processes and accelerate translation life cycles. Merrill Brink is certified to ISO 9001:2008; ISO 27001:2005 and ISO 13485:2003, and registered to EN 15038:2006 and ISO 14971:2007. Together, these standards provide assurance that the most stringent process and quality standards for translation are followed. Merrill Brink International is a wholly owned subsidiary of Merrill Corporation.


Contact

Attachments